Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. LGVN
LGVN logo

LGVN

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

LGVN News

Avaí Bio Initiates Production of α-Klotho Cell Bank

Mar 18 2026Globenewswire

Avaí Bio Initiates Production of α-Klotho Cells

Mar 18 2026PRnewswire

Avaí Bio Initiates α-Klotho Cell Production

Mar 18 2026Newsfilter

Longeveron (LGVN) Q4 2025 Earnings Call Transcript

Mar 18 2026NASDAQ.COM

Longeveron Reports FY EPS Beat but Increased Losses

Mar 17 2026seekingalpha

Longeveron Raises $15M to Advance Laromestrocel Therapy

Mar 10 2026Benzinga

Avaí Bio Advances Cell Therapy Production Milestone

Mar 03 2026PRnewswire

Avaí Bio Advances α-Klotho Cell Production Milestone

Mar 03 2026Newsfilter

Longeveron Inc. Reports Positive Trial Results for Age-Related Therapy

Feb 25 2026stocktwits

Longeveron Reports Positive Phase 2b Clinical Trial Results

Feb 25 2026Newsfilter

Longeveron Appoints New CEO Stephen H. Willard

Feb 13 2026seekingalpha

Longeveron Appoints New CEO to Drive Growth

Feb 13 2026Newsfilter

Pediatric Priority Review Voucher Program Reauthorized

Feb 05 2026Newsfilter

Longeveron Secures Japanese Patent for Stem Cell Therapy Assays

Jan 29 2026Newsfilter

Longeveron Joins JPM Healthcare Week to Focus on Alzheimer's Disease

Dec 29 2025Globenewswire

Longeveron Joins Alzheimer's Health Moonshot Initiative During JPM Healthcare Week

Dec 29 2025Newsfilter